GILEAD SCIENCES INC
For the period ended May 8, 2024. Filed Mar 28, 2024.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
May 8, 2024 · Filed Mar 28, 2024
Contents
Cover page
Show cover page
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE 14A
PROXY STATEMENT PURSUANT TO SECTION 14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. )
| Filed by the Registrant | Filed by a Party other than the Registrant |
Check the appropriate box:
Preliminary Proxy Statement
Confidential, for Use of the Commission Only (as permitted by Rule 14A-6(E)(2))
Definitive Proxy Statement
Definitive Additional Materials
Soliciting Material under §240.14a-12
Gilead Sciences, Inc.
(Name of Registrant as Specified in Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
No fee required.
Fee paid previously with preliminary materials.
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
| OUR VISION To create a healthier world for all people OUR MISSION To discover, develop and deliver innovative therapeutics for people with life-threatening diseases OUR CORE VALUES Integrity Doing What’s Right Inclusion Encouraging Diversity Excellence Being Your Best Teamwork Working Together Accountability Taking Personal Responsibility OUR CORPORATE STRATEGY | |||
| LONG-TERM AMBITIONS | STRATEGIC PRIORITIES | ||
| (Refreshed in 2023) | |||
| Bring 10+ Transformative Therapies to Patients by 2030 | ► Maximize Near-Term Revenue Growth ► Maximize Impact of Long-acting HIV Therapies ► Expand and Deliver on Oncology Programs | ||
| Be a Biotech Employer and Partner of Choice | ► Champion an Environment of Inclusion and Employee Growth ► Remove Barriers to Speed in Execution | ||
| Deliver Shareholder Value in a Sustainable, Responsible Manner | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.